These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1910082)

  • 41. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017).
    Mulder JW; Cooper DA; Mathiesen L; Sandström E; Clumeck N; Gatell JM; French M; Donovan B; Gray F; Yeo JM
    AIDS; 1994 Mar; 8(3):313-21. PubMed ID: 7913326
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pilot phase I study using zidovudine in association with a 10-day course of anti-CD4 monoclonal antibody in seven AIDS patients.
    Dhiver C; Olive D; Rousseau S; Tamalet C; Lopez M; Galindo JR; Mourens M; Hirn M; Gastaut JA; Mawas C
    AIDS; 1989 Dec; 3(12):835-42. PubMed ID: 2576628
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quantification of HIV-1 virus load under zidovudine therapy in patients with symptomatic HIV infection: relation to disease progression.
    Molina JM; Ferchal F; Chevret S; Barateau V; Poirot C; Morinet F; Modai J
    AIDS; 1994 Jan; 8(1):27-33. PubMed ID: 7912084
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical and laboratory characteristics of HIV-1 infection in Zimbabwe.
    Katzenstein DA; Latif AS; Grace SA; Basset M; Mashu A; de Villiers DM; Carrow EW; Hendry RM; Marowa E; Emmanuel JC
    J Acquir Immune Defic Syndr (1988); 1990; 3(7):701-7. PubMed ID: 1972189
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Behaviour of different clinical, immunological and serological parameters observed in a group of HIV positive patients during a 12 month treatment period with zidovudine.
    Crocchiolo PR; Lizioli A; Arcidiacono I; Cantaluppi P; Filippi C; Sobatti D; Bedarida G; D'Agostino F; Cambie G; Nardella ML
    Boll Ist Sieroter Milan; 1990 Jun; 69(2):423-30. PubMed ID: 1983798
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study.
    Merigan TC; Skowron G; Bozzette SA; Richman D; Uttamchandani R; Fischl M; Schooley R; Hirsch M; Soo W; Pettinelli C
    Ann Intern Med; 1989 Feb; 110(3):189-94. PubMed ID: 2536257
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The efficacy and toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex (ARC): an open uncontrolled treatment study.
    Stambuk D; Youle M; Hawkins D; Farthing C; Shanson D; Farmer R; Lawrence A; Gazzard B
    Q J Med; 1989 Feb; 70(262):161-74. PubMed ID: 2512592
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.
    Larder BA; Darby G; Richman DD
    Science; 1989 Mar; 243(4899):1731-4. PubMed ID: 2467383
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quantitation of human immunodeficiency virus in vertically infected infants and children.
    Alimenti A; Luzuriaga K; Stechenberg B; Sullivan JL
    J Pediatr; 1991 Aug; 119(2):225-9. PubMed ID: 1677684
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and efficacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3: a double-blind placebo-controlled trial.
    Goldstein G; Conant MA; Beall G; Grossman HA; Galpin JE; Blick G; Calabrese LH; Hirsch RL; Fisher A; Stampone P
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Mar; 8(3):279-88. PubMed ID: 7859140
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Immunohistologic study of the significance of the Hofbauer cell for the transplacental HIV infection chain].
    Jimenez E; Unger M; Bläss G; Schäfer A
    Arch Gynecol Obstet; 1989; 245(1-4):171-2. PubMed ID: 2508577
    [No Abstract]   [Full Text] [Related]  

  • 52. Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection.
    Godfried MH; van der Poll T; Mulder JW; Weverling GJ; Endert E; Lange JM; Sauerwein HP
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):531-9. PubMed ID: 8548332
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Markers for progression to acquired immune deficiency syndrome and zidovudine treatment of asymptomatic patients.
    Lange JM; de Wolf F; Mulder JW; Coutinho RA; van der Noordaa J; Goudsmit J
    J Infect; 1989 Jan; 18 Suppl 1():85-91. PubMed ID: 2492586
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Allogeneic bone marrow transplantation, zidovudine, and human immunodeficiency virus type 1 (HIV-1) infection. Studies in a patient with non-Hodgkin lymphoma.
    Holland HK; Saral R; Rossi JJ; Donnenberg AD; Burns WH; Beschorner WE; Farzadegan H; Jones RJ; Quinnan GV; Vogelsang GB
    Ann Intern Med; 1989 Dec; 111(12):973-81. PubMed ID: 2512828
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudine.
    Jacobson MA; De Gruttola V; Reddy M; Arduino JM; Strickland S; Reichman RC; Bartlett JA; Phair JP; Hirsch MS; Collier AC
    AIDS; 1995 Jul; 9(7):727-34. PubMed ID: 7546418
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence on survival of p24 antigen levels in patients with AIDS or advanced AIDS related complex treated with zidovudine.
    Zamora L; Gatell JM; Barrera JM; Ercilla G; Gil C; Buira E; Miro JM; Soriano E
    Eur J Clin Microbiol Infect Dis; 1992 Dec; 11(12):1181-5. PubMed ID: 1291319
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Zidovudine-interferon-alpha combination therapy in patients with advanced human immunodeficiency virus type 1 infection: biphasic response of p24 antigen and quantitative polymerase chain reaction.
    Edlin BR; Weinstein RA; Whaling SM; Ou CY; Connolly PJ; Moore JL; Bitran JD
    J Infect Dis; 1992 May; 165(5):793-8. PubMed ID: 1349031
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Statistical methods for the analysis of HIV-1 core polypeptide antigen data in clinical studies.
    Makuch RW; Parks WP
    AIDS Res Hum Retroviruses; 1988 Aug; 4(4):305-16. PubMed ID: 3061416
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HIV-1 inhibition by azidothymidine in a concurrently randomized placebo-controlled trail.
    Parks WP; Parks ES; Fischl MA; Leuther MD; Allain JP; Nusinoff-Lehrman S; Barry DW; Makuch RW
    J Acquir Immune Defic Syndr (1988); 1988; 1(2):125-30. PubMed ID: 3145972
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Following up indeterminate HIV-1 western blots.
    Couroucé AM
    Lancet; 1989 Dec; 2(8675):1330-1. PubMed ID: 2574271
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.